SeaStar Medical Holding Corporation (ICU) Earnings Call Transcript & Summary
November 11, 2026
Earnings Call Speaker Segments
Jackie Cossmon
executiveThanks, Latif. Good afternoon, and I appreciate everyone joining us for SeaStar Medical's Third Quarter 2026 Financial Results Conference Call. This is Jackie Cosman, with Wheelhouse Life Science Advisors. With me today from SeaStar Medical are Eric Schlorff, our Chief Executive Officer; Tim Varacek, Senior Vice President of Commercial and Business Operations; Dr. David Chung, Chief Medical Officer; and Mike Messinger, Chief Financial Officer. A quick reminder for listeners: management's remarks on this call will contain forward-looking statements as defined under federal securities laws, and those statements carry risks and uncertainties that may cause actual results to differ materially from any results we anticipate. For a listing and description of these risks and uncertainties, please review SeaStar Medical's filings with the Securities and Exchange Commission. Also, the information on this conference call is accurate only as of the date of the live broadcast, November 11, 2026. SeaStar Medical has no obligation to revise or update any statements to reflect events or circumstances, except as required by law. With that, I'll hand the call to Eric. Eric?
Eric Schlorff
executiveThanks, Jackie, and thanks everybody for being with us today. We moved forward well on a number of fronts during this quarter. Demand for QUELIMMUNE was strong in the ultrarare pediatric AKI market, and we're keeping up the momentum in educating the pediatric critical care health care community. Our CMO, Kevin Chung, presented QUELIMMUNE data at multiple medical meetings, and we're already telling critical care professionals about the statistically significant higher survival among QUELIMMUNE-treated patients in our patient registry that was featured in the late-breaking presentation at ASN Kidney Week 2026. What matters here is that we believe this expanding surge of interest reinforces the potential of our SCD therapy across the indications in our pipeline — starting with adults who have AKI and are receiving continuous renal replacement therapy, or CRRT. Our neutralized AKI pivotal trial in that population is progressing well, having enrolled about 75% of the 339 patients it is designed to include. Findings from this study will be essential for grasping how our SCD therapy might help avert a lifetime of dialysis and help save patients' lives. As we've noted previously, participation in this trial is governed by rigorous inclusion and exclusion criteria intended to bring in the patients best suited to the study, and that gives us a clearly defined trial population along with a more rigorous assessment of the potential benefit of SCD for these patients. Because of that, we're revising our guidance on when enrollment will be finished. At the enrollment rate we're seeing now, we would anticipate wrapping up the trial around the middle of 2027. As we continue opening additional sites and collaborate with our existing sites to ensure they have full support for recruiting and enrolling patients, that timeline might move up, though at present we prefer to stay conservative in our forecast. Obviously, we're not pleased about pushing back the timeline for finishing enrollment. Still, our top concern is running the study in a way that gives our SCD therapy the best shot at an optimal result and, in the end, gets it to patients. Moving on to the premarket approval, or PMA, application for the adult AKI indication: we're working concurrently to speed up the route to approval by getting PMA modules ready and sent to the FDA before we submit the neutralized AKI clinical results. The first module is in, and we're getting further modules ready to send over the next several months. In addition, the breakthrough device designation we hold for this indication ought to allow a priority review of the PMA after we file the final module containing the neutralized AKI clinical results, assuming the trial reads out positively. A further notable development during the quarter was the FDA granting Breakthrough Device designation for our SCD therapy, aimed at treating hyperinflammation in adults suffering from sepsis or a septic condition. Before Kevin explains why this indication is significant, I want to stress that it reflects a major unmet need. Our current neutralized AKI study was designed with a prespecified analysis intended to capture potential benefit from the SCD therapy in sepsis patients. When that trial concludes, we should therefore have considerable data demonstrating how the SCD therapy may work as a treatment for people with AKI and sepsis. Before I turn things over to Tim so he can discuss how we intend to keep expanding QUELIMMUNE adoption, I’d like to recognize those in our armed forces who are being honored today—among them Kevin, whose military service included work as a combat physician. In fact, Kevin was recently presented with the Combat Nephrology award during the update in Critical Care Nephrology meeting held in Madrid, Spain, where he also delivered the keynote address. That honor exists to spotlight clinicians, researchers, and military medical officers whose work has brought about transformative improvements in renal support under conditions of extreme high acuity, trauma, and combat casualty care. His peers in the field bestowed it, and I know receiving it meant a great deal to Kevin. Kevin’s commitment and enthusiasm when it comes to looking after patients truly stand out — and his efforts at SeaStar show he genuinely battles to rescue every single person; so well done, Kevin, on an honor you thoroughly earned. With that said, I’ll now hand things over to Tim.
Tim Varacek
executiveThanks, Eric, and thank you all for being with us today. As Eric mentioned, QUELIMMUNE demand was strong in the quarter, and we're keeping up the momentum in educating the pediatric critical care and nephrology community. Our main objective remains growing the market so that every pediatric AKI patient gets the chance to receive QUELIMMUNE therapy. Net revenue from QUELIMMUNE sales rose sharply to more than $630,000 for the quarter, up 247% from net revenue in last year's third quarter. And 9 months net revenue more than doubled, reaching $1.7 million, which positions us to surpass our guidance of $2 million in quelamine revenue for the year; so we're quite excited about the growing enthusiasm for our QUELIMMUNE therapy in this ultra-rare condition and expect that to carry into 2027. On top of that, a number of recent developments cleared the way toward potentially smoother customer adoption going forward; among them, FDA's confirmation that we've satisfied the requirements of the mandatory post-approval Save registry, which had previously added considerable institutional time and effort to the QUELIMMUNE adoption process within pediatric hospital systems; and, as we reported recently, CMS's assignment of ICD-10-PCS codes will give hospitals the ability to track and bill for procedures that use the QUELIMMUNE therapy. Now, regarding our strategy for 2027 and beyond, because this condition is ultra-rare, we will keep our focus on the top 50 pediatric medical centers as the primary target for QUELIMMUNE adoption. Twenty of these top 50 medical institutions are customers today, and we expect utilization with existing customers to keep increasing. We've added 10 new customers so far in 2026 and plan to keep pushing to bring on new customers throughout this year and beyond. Based on outcomes data we've observed and that has been published, we believe our ongoing focus on QUELIMMUNE education and expansion could potentially save lives in the pediatric patient population and also lay the foundation for a possible launch in adult AKI, a much larger and underserved population of patients; so thank you for your attention. With that, I'll hand the presentation over to our Chief Medical Officer, Kevin Chung. Kevin?
Kevin Chung
executiveThanks, Tim, and thanks to all of you for joining the call, and thank you, Eric, for the kind words. Throughout my whole career I've been caring for the sickest patients in the hospital. To start, as an army critical care physician looking after critically ill combat wounded, and then through the COVID pandemic and after. One idea has stayed with me: patients who have multiple organ failure, along with their families, deserve better options. The current standards of care simply aren't good enough. Before I move on to neutralize AKI, I want to talk about the SAVE Registry results that we presented at ASN Kidney Week 2026 in late October. Choosing this data as a late breaker shows how urgently better options are needed for children with sepsis associated AKI; it's hard to convey just how sick these children are. A lot of them are battling sepsis and multiple organ failure simultaneously, and a substantial number were on extracorporeal membrane oxygenation, or ECMO, while nearly all needed invasive mechanical ventilation and vasopressor use to treat circulatory shock. ECMO was used in roughly 1/3 of patients. Historically, fewer than half of these kinds of patients survive. From a safety assessment standpoint, no device-related adverse events were reported across 50 treated patients. That matters because these children are so fragile that a complication from the therapy itself could cause potential harm. Now on survival: we did a comparison of patients treated with QUELIMMUNE against a clinically matched group drawn from the kids inpatient database, or KID, which is the biggest all-payer pediatric inpatient database publicly available in the United States. What that showed was 90-day survival of 65% among QUELIMMUNE-treated patients versus 47% in the KID cohort, and that difference was statistically significant, with a p-value of 0.043. Survival at 60 days and in-hospital survival were also statistically significant; and among the QUELIMMUNE-treated patients who did not need renal replacement therapy, or RT, at baseline, 83% were independent of RT at 90 days. From my perspective as a critical care physician, the greater survival we've seen among these children—this very ill group—is quite heartening; that's exactly why we continue pushing to teach pediatric nephrologists and intensivists about QUELIMMUNE and where it fits within its approved indication. Moving on now to our pivotal trial of neutralized AKI: a randomized, controlled study built to evaluate SCD therapy in critically ill adults with AKI who require CRT. The main endpoint combines mortality or dialysis dependence at 90 days; to date we've enrolled 251 of the 339 patients we anticipate in total, and we've kept up site recruitment to speed enrollment along. We just brought on 4 more clinical sites, and there are other sites we're working to get activated by year-end. As Eric said, we're using our present enrollment rate to set a timeline of midyear 2027 for finishing patient enrollment, though we're working hard daily to recruit patients as fast as we can. As we've mentioned previously, the enrollment rate, which has been fairly stable, is partly shaped by our eligibility criteria — these are deliberately narrow so that we enroll patients whose disease can be modified. Eric also mentioned that we're actively pursuing premarket approval, or PMA, with the FDA, which could potentially speed up the overall approval path for this important indication. Through the modular PMA, the FDA can review and approve parts of our application before the trial finishes. The clinical data module gets submitted once the trial is complete, assuming the results we see are positive. Last, I want to discuss the recent news about the FDA's decision to award us breakthrough device designation for the potential treatment of adult sepsis patients. Sepsis is still a top cause of preventable death, rehospitalization, and long-term functional or cognitive impairment. In the U.S., sepsis plays a role in 1 in 3 hospital deaths. This FDA decision highlights a substantial unmet need in sepsis treatment, which remains among the toughest conditions we deal with in critical care. The main reason is that addressing the infection by itself may not stop the unregulated immune reaction that leads to organ damage. Our SCD treatment is designed to adjust that reaction selectively, rather than suppressing the immune system across the board. That is why, in our protocol for the ongoing neutralize AKI pivotal clinical trial, we included a prespecified statistical analysis of the subset of adult patients with AKI and sepsis. As a result, we anticipate having meaningful data to present to the FDA for this indication soon. Assuming things turn out well, our plan is to move quickly on sending the pertinent data to the FDA and to discuss what comes next in helping these patients, who right now have limited choices for treating sepsis effectively. I would add that this marks the seventh indication for which the SCD therapy has earned breakthrough device designation. That designation shows the FDA has concluded the relevant criteria are satisfied, among them a reasonable expectation that the technology might offer more effective treatment for a condition that is life-threatening or irreversibly debilitating. We think having this many designations supports the idea that the SED platform can work regardless of disease, targeting this regulated inflammation in a range of serious conditions. We remain dedicated to producing the clinical evidence required to move these indications forward. On that note, I'll turn things over to our CFO, Mike Messinger. Mike?
Michael Messinger
executiveThanks, Kevin, and I appreciate everyone being with us today. I'll give you a quick summary of the financial results we posted for the third quarter of 2026. Just to note, our Form 10-Q is going to be filed with the SEC over the next 24 hours, and it will contain a more detailed discussion of the company's financial results for the 3 months ended September 30, 2026. That 10-Q will be available at sec.gov or on our website, seastarmedical.com. For the third quarter, we recorded net revenue of roughly $635,000, which reflects stronger demand for QUELIMMUNE; that works out to a 247% increase versus net revenue of approximately $183,000 in the third quarter of 2025; and we kept our gross profit percentage above 90% in the third quarter of 2026, in line with what we saw in earlier quarters this year. Now let's look at operating expenses. Operating expenses came in at $5.2 million for the third quarter of 2026, versus $3.7 million in the third quarter of 2025. Our research and development expenses — they rose mainly because of greater clinical research activity tied to the neutralize AKI pivotal study, along with SCD development expenses and personnel costs, when compared with the same period in 2025. Our general and administrative spending was down from the third quarter of 2025, largely because of lower personnel costs, plus a reduction in legal, audit and SEC-related expenses. Those decreases were partly offset by higher professional services, director fees and franchise taxes. For the third quarter of 2026, net loss was about $4.5 million, or $1.03 per share, on weighted average shares outstanding of roughly 4.4 million shares. That compares to a net loss of approximately $3.5 million, or $1.30 per share, in the third quarter of 2025, on weighted average shares outstanding of approximately 2.7 million; on our balance sheet at September 30, 2026, we had about $4 million in cash, versus approximately $12 million at December 31, 2025, and — our cash balance as of September 30, 2026, does not include the $3.3 million in gross proceeds from warrant exercises that took place in October.
Eric Schlorff
executiveAnd at this point I'll hand things back over to Eric. Thank you, Mike. For today's third quarter financial results conference call, what we aimed to do was give everyone a summary of the progress we've made and a clear view of the opportunities that lie ahead of us. We feel strongly about what we can do by delivering a life-saving therapy to critically ill patients who right now have no other option for calming the cytokine storm that an overactive immune system produces. The opportunities ahead for SeaStar Medical, we believe, are significant, and we look forward to sharing our future progress with you. With that, I'll ask the operator to open up the call for questions.
Dave Bautz
analystThanks for the update today. My first question: given that the expected enrollment timeline has slipped a bit, can you update us on the timeline running from finishing enrollment through to top-line data and then the final PMA submission?
Eric Schlorff
executiveYes. Thanks, David, for joining and for the question. Based on the estimated timeline for completing enrollment, I would say we expect to file the final PMA module roughly 9 months after enrollment is complete?
Dave Bautz
analystAll right, I'd like to dig into a few QUELIMMUNE figures, if that's okay. At present, what number of hospitals are your customers? And after that, how many — how many are treating patients? Could you also tell me the count of patients who received treatment in Q3, Q2, or both quarters? And the sales were fairly level between Q2 and Q3. I'm just curious whether you might explain what accounted for that.
Eric Schlorff
executiveYes. Appreciate the question. Tim, would you like to take that one?
Tim Varacek
executiveAbsolutely, and I appreciate the question. So as I said earlier, we currently have 20 customers. Essentially, every one of them is using the product. As for when they use it, that really depends on their census and on which patients come in who are eligible for QUELIMMUNE therapy. Most of the customers we have are repeat customers, and they use it whenever they can for their patients. On the question of revenue being flat compared with Q2, the comparison I would point to is where we stood in Q3 of last year, which is what we discussed earlier; but what we are seeing is momentum building and enthusiasm growing around the product. The aim here is to keep adding new sites. Then, as we bring those sites on, to make sure we educate them properly so that they can identify patients and treat them. That is the work. You have to keep in mind that this is an ultra-orphan population. So it is not the case that a vast majority of patients are constantly crashing into the hospital; it really is a unique condition, and there are specialized hospitals capable of handling those patients, and those are the hospitals we are focused on.
Dave Bautz
analystAll right, great. And for the final question, now that the SAVE registry requirements have been satisfied, are you noticing any shifts in hospital adoption or utilization, or in your capacity to onboard new hospital customers?
Eric Schlorff
executiveYes. Thanks again for asking, David. Tim, I believe that one falls to you too.
Tim Varacek
executiveYes, absolutely. This is quite recent. But what we’re seeing is a strongly favorable reaction to the SAVE Registry when it comes to meeting that requirement. I’ve gotten emails myself from customers who are now in the pipeline and progressing through the process, and they’re enthusiastic about it. We really believe it will have a beneficial impact on the broader willingness to bring QUELIMMUNE into the hospital, since practically every customer we speak with is highly interested in the device and the technology. And at times, what matters is resources, time lines, or how much effort they need to put in; so the fact that the registry is no longer mandatory lowers that overall effort level. And it does make it a more appealing option for some of those hospital systems that had been waiting for something like this to occur.
Anthony Vendetti
analystFirst off, I'd like to congratulate Kevin as well. After meeting him, I can't say I'm surprised; and on Veterans Day, it's certainly worth pausing to acknowledge. So congratulations, Kevin. Now, my question concerns the breakthrough device designation. I understand this is your seventh one, using SCD therapy for adult patients with sepsis or a sepsis condition, correct? Could you expand a bit on what you expect the timeline to look like for getting that cleared through the FDA? What needs to happen right now to move that process along quickly, if that's possible? Or are you basically waiting for them to review it and come back with a plan?
Eric Schlorff
executiveNo. Thanks, Anthony, and thanks for being with us today. So one thing you need to keep in mind. The breakthrough device designation is structured in a way that lets us hold early conversations with the FDA much more promptly. So, as Kevin alluded to, we actually proactively designed the study with some prespecified elements across 2 different populations, subpopulations: one was sepsis, and one was for ARDS, or acute respiratory distress syndrome. So all of that was preplanned. And so as we keep finishing enrollment and again, the number or percentage of patients who will have sepsis or a receptive condition will likely be probably north of 70% of the total patients here. And so we will, in parallel, have discussions with the FDA about that subpopulation as we complete enrollment and then obviously have discussions as we conduct the final analysis on the back end after, obviously, the last patient has been enrolled and goes through the process of getting the top line results.
Anthony Vendetti
analystOkay, great, all right, so you'll handle that at the same time. And then perhaps — well, this is probably better directed at Michael. For the 2016 full-year guidance, clearly we've only got 1 quarter remaining, it was around $2 million. I don't notice any revised guidance in the report. Does that suggest it simply stays at the same guidance? Or have there been any adjustments there?
Eric Schlorff
executiveMike, go ahead and answer, you got this.
Michael Messinger
executiveSure. Thank you, Eric. Thank you, Anthony, and it's nice to hear from you. So, as Tim said, we think we're going to beat our guidance for the year. We aren't putting out a number right now. Clearly, this is an incidence-based indication. But we feel really good about our guidance. And clearly, we'll aim to give 2027 guidance earlier in 2027. So I think we're in good shape where we stand, if that makes sense to you.
Anthony Vendetti
analystAll right, got it. So then, clearly, Eric, I believe you've more or less addressed this, right? If the trial wraps up by midyear '27 and you file roughly 9 months following completion, that would mean filing perhaps in first quarter '28, and then the expected approval would be maybe first quarter '29 or first half '29 — is that how we ought to think about it?
Eric Schlorff
executiveWell, essentially that's the FDA's guidance, since they have 180 days. Clearly, that isn't something within our control, but it's also the reason we're assembling these modular PMAs the way we are — so that we may be able to shorten any of the final module, or the clinical results for that — for the study.
Anthony Vendetti
analystAll right. All right, so as you mentioned, it might happen earlier, though the midpoint of '27 for completion is what your guidance currently says.
Jackie Cossmon
executiveThanks, Latif, and thanks to everyone for being with us today for the C-star Medical Third Quarter Financial Results Conference Call. Should you have any questions, please reach out to us at ir@cstarmed.com, or stop by our website at www.starmedical.com. Thanks, and goodbye.
Operator
operatorThis concludes today's conference call. Thank you for participating. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete SeaStar Medical Holding Corporation transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to SeaStar Medical Holding Corporation earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in SeaStar Medical Holding Corporation or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.